Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

• Main Authors: Katie Lloyd (Author), Stamatia Papoutsopoulou (Author), Emily Smith (Author), Philip Stegmaier (Author), Francois Bergey (Author), Lorna Morris (Author), Madeleine Kittner (Author), Hazel England (Author), Dave Spiller (Author), Mike H. R. White (Author), Carrie A. Duckworth (Author), Barry J. Campbell (Author), Vladimir Poroikov (Author), Vitor A. P. Martins dos Santos (Author), Alexander Kel (Author), Werner Muller (Author), D. Mark Pritchard (Author), Chris Probert (Author), Michael D. Burkitt (Author), The SysmedIBD Consortium (Author)
• Format: Book
• Published: The Company of Biologists, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Inflammatory bowel diseases (IBDs) cause significant morbidity and mortality. Aberrant NF-κB signalling is strongly associated with these conditions, and several established drugs influence the NF-κB signalling network to exert their effect. This study aimed to identify drugs that alter NF-κB signal...